Osama Hamdy
Endocrinology, Diabetes & Metabolism · Boston, MANPI 1902841596
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Sanofi-aventis U.S. LLC accounts for 68.3% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $73,524 and has fallen 96.2% since, to $2,805 in 2025. Among endocrinology, diabetes & metabolism clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 40 payments — averaging $2915.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$80K
- AstraZeneca$10K
- Upjohn US 1 LLC$6K
- Takeda$5K
- Gilead$4K
- Novo Nordisk$4K
- plus $8K from 5 others
Across 1,155 payments — averaging $854.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$475K
- Novo Nordisk AS$457K
- Mannkind Corporation$55K
- Novo Nordisk$48
What the payments were for
- Consulting fees$32,02227%
- Speaking & faculty fees$67,54058%
- Travel & lodging$16,70314%
- Food & beverage$3420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 17 | $79,670 |
| AstraZeneca | 1 | $9,765 |
| Upjohn US 1 LLC | 1 | $6,400 |
| Takeda | 1 | $5,000 |
| Gilead | 10 | $3,936 |
| Novo Nordisk | 3 | $3,915 |
| BD | 1 | $3,750 |
| Insulet Corporation | 2 | $2,099 |
| Mylan Inc. | 1 | $2,000 |
| Abbott | 2 | $56 |
| Inspire Medical Systems, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$116,606 in reported general payments places this provider in the 95th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
See all endocrinology, diabetes & metabolism providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 135 | $196,921 |
| TrulicityDulaglutide | 94 | $176,454 |
| JardianceEmpagliflozin | 144 | $173,282 |
| OzempicSemaglutide | 91 | $163,384 |
| Tresiba Flextouch U-200Insulin Degludec | 55 | $80,251 |
| FarxigaDapagliflozin Propanediol | 43 | $60,074 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $47,245 |
| JanuviaSitagliptin Phosphate | 24 | $36,054 |
| JanumetSitagliptin Phos/Metformin Hcl | 33 | $28,117 |
| TradjentaLinagliptin | 21 | $23,427 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $19,393 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 19 | $9,105 |
| Humalog Kwikpen U-100Insulin Lispro | 16 | $8,090 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 37 | $6,286 |
| Admelog SolostarInsulin Lispro | 12 | $5,603 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $3,915 | $163,38491 claims |
| AstraZenecaFarxiga | $9,765 | $60,07443 claims |
| Mylan Inc.Atorvastatin Calcium | $2,000 | $1,12677 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
Other endocrinology, diabetes & metabolism in Boston
- Jason GagliaBoston$2.4M
- Vanita ArodaBoston$482K
- Michael RosenblattBoston$447K
- Steven RussellBoston$445K
- Beverly BillerBoston$346K
- Christos MantzorosBoston$243K
- Augusto Caballero-RoblesBoston$150K
- Barbara KahnBoston$105K
- Naomi FisherBoston$79K
- Andrea CovielloBoston$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.